Increased Heart Rate and Haemostatic Balance Disorders Pre-exist the Established Hypertension
暂无分享,去创建一个
F. Triposkiadis | M. Kyriakidis | T. Makris | P. Krespi | G. Stavroulakis | A. Hatzizacharias | T. Mandalaki | C. Tsoukala
[1] K. Kavaklı,et al. Plasma Platelet-activating Factor (PAF) Levels and Desmopressin Response in Children with Hemophilia A and von Willebrand's Disease , 1999, Thrombosis and Haemostasis.
[2] G. Siest,et al. Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas Cohort. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[3] G. Lip,et al. Relation of endothelium, thrombogenesis, and hemorheology in systemic hypertension to ethnicity and left ventricular hypertrophy. , 1997, The American journal of cardiology.
[4] A. Rumley,et al. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[5] T. Makris,et al. Haemostasis balance disorders in patients with essential hypertension. , 1997, Thrombosis research.
[6] S. Julius,et al. Heart rate and the cardiovascular risk , 1997, Journal of hypertension.
[7] I. Mattiasson,et al. Coagulation and fibrinolytic factors in normotensive hypertension-prone men , 1996, Journal of hypertension.
[8] J. Zehnder,et al. Recurrent thrombosis due to compound heterozygosity for factor V Leiden and factor V deficiency. , 1996, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[9] P. Simioni,et al. “Pseudo Homozygous” Activated Protein C Resistance due to Double Heterozygous Factor V Defects (Factor V Leiden Mutation and Type I Quantitative Factor V Defect) Associated with Thrombosis: Report of Two Cases Belonging to Two Unrelated Kindreds , 1996, Thrombosis and Haemostasis.
[10] P. Lund-johansen,et al. The Bergen Blood Pressure Study: prehypertensive changes in cardiac structure and function in offspring of hypertensive families. , 1995, Blood pressure.
[11] B. Dahlbäck,et al. Activated protein C resistance: from phenotype to genotype and clinical practice. , 1995, Blood reviews.
[12] M. Woodward,et al. Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease, and family history: the Scottish Heart Health Study. , 1993, British heart journal.
[13] J. Feldman,et al. Pulse rate, coronary heart disease, and death: the NHANES I Epidemiologic Follow-up Study. , 1991, American heart journal.
[14] U. Smith,et al. Elevated fibrinogen and plasminogen activator inhibitor (PAI‐1) in hypertension are related to metabolic risk factors for cardiovascular disease , 1990, Journal of internal medicine.